Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 -2026

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 -2026

  • February 2019 •
  • 184 pages •
  • Report ID: 5750465 •
  • Format: PDF
Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview
This report analyzes the current and future scenario of the global chronic obstructive pulmonary disease (COPD) treatment market.Rise in prevalence of COPD, increase in the adoption of combination therapy, and surge in awareness about COPD treatment are the key factors anticipated to drive the global market.

Additionally, increase in the geriatric population, rise in importance of COPD management, and surge in the number of respiratory care centers contribute to the growth of the global market. According to the Global Initiative for Asthma (GINA) 2018, COPD is the third leading cause of death in the U.S., with large portion of population being undiagnosed.

The global chronic obstructive pulmonary disease treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.It also provides information and data analysis of the global market with respect to the segments based on drug class, distribution channel, and region.

A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section.Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market.

This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global chronic obstructive pulmonary disease treatment market.

New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market.In February 2016, Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments.

This collaboration aims to connect these medications to Propeller’s digital health platform..

Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Segments
In terms of drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm and others.The combination segment has been divided into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others.

The bronchodilators segment has been classified into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA).Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

The retail pharmacies segment is projected to expand at the fastest CAGR due to increase in the number of patients preferring retail pharmacies. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Regional Outlook
In terms of region, the global chronic obstructive pulmonary disease treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report
The report also profiles major players in the global chronic obstructive pulmonary disease treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd, Mylan N.V., and Orion Corporation.

The global chronic obstructive pulmonary disease treatment market has been segmented as below:
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class
Combination
Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
Triple Therapy
Others

Bronchodilators
Long Acting Beta Agonist (LABA)
Short Acting Beta Agonist (SABA)
Long Acting Muscarinic Antagonist (LAMA)
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Mucokinetics
Others

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa